EX-99.1
4
ex991.htm
EXHIBIT 99.1
Exhibit 99.1
Exhibit
99.1
Urigen
N.A., Inc. Completes Reverse Merger With Valentis, Inc.
BURLINGAME,
Calif. July 16, 2007 --(BUSINESS WIRE)-- Urigen N.A., Inc., a specialty
pharmaceutical company focused on the development of treatments for urological
disorders, has successfully completed its reverse merger into Valentis, Inc.
on
July 13, 2007. As a result, the Company plans to change its name to Urigen
Pharmaceuticals, Inc. However, until such event unfolds, the Company will
continue to trade on the Bulletin Board under the Valentis Inc. symbol
(VLTS).
"We
are
pleased to have established Urigen as a publicly traded specialty pharmaceutical
company focusing on urological disorders", said William Garner, Urigen's Chief
Executive Officer. "Our management team continues to successfully execute our
business plan and we look forward to routinely communicating our progress to
our
shareholders".
About
Urigen N.A., Inc.
Urigen
N.A. is a specialty pharmaceutical company dedicated to the development and
commercialization of therapeutic products for urological disorders. Urigen's
two
lead programs target significant unmet medical needs and major market
opportunities in urology. Urigen's URG101 project targets chronic pelvic pain
of
bladder origin, which affects approximately 10.5 million men and women in North
America. Urigen's URG301 project targets acute urgency in patients diagnosed
with an overactive bladder, another major unmet need that is insufficiently
managed by presently available overactive bladder drugs. URG301 is a proprietary
dosage form of an approved drug that is locally delivered to control urinary
urgency. For further information, please visit Urigen's website at
http://www.urigen.com.
Forward-Looking
Statement
This
press release may contain forward-looking statements. These statements may
be
identified by the use of forward-looking terminology such as "anticipate,"
"believe", "continue", "could", "estimate", "expect", "intend", "may", "might,"
"plan", "potential", "predict", "should", or "will", or the negative thereof
or
other variations thereon or comparable terminology. Urigen has based these
forward-looking statements on current expectations, assumptions, estimates
and
projections. While Urigen believes that these expectations, assumptions,
estimates and projections are reasonable, such forward-looking statements are
only predictions and involve known and unknown risks and uncertainties, many
of
which are beyond its control. Given these risks and uncertainties, investors
and
securityholders are cautioned not to place undue reliance on such
forward-looking statements. Urigen does not undertake any obligation to update
any such statements or to publicly announce the results of any revisions to
any
such statements to reflect future events or developments.
Contact:
Urigen
N.A., Inc.
Martin
E.
Shmagin, 650-259-0239
Chief
Financial Officer
www.urigen.com
or
The
Investor Relations Group
Investor
Relations:
Adam
Holdsworth/Rachel Colgate
212-825-3210

EX - 99 . 1 4 ex991 . htm EXHIBIT 99 . 1 Exhibit 99 . 1 Exhibit 99 . 1 Urigen N . A . , Inc . Completes Reverse Merger With Valentis , Inc . BURLINGAME , Calif . July 16 , 2007 -- ( BUSINESS WIRE ) -- Urigen N . A . , Inc . , a specialty pharmaceutical company focused on the development of treatments for urological disorders , has successfully completed its reverse merger into Valentis , Inc . on July 13 , 2007 . As a result , the Company plans to change its name to Urigen Pharmaceuticals , Inc . However , until such event unfolds , the Company will continue to trade on the Bulletin Board under the Valentis Inc . symbol ( VLTS ) . " We are pleased to have established Urigen as a publicly traded specialty pharmaceutical company focusing on urological disorders " , said William Garner , Urigen 's Chief Executive Officer . " Our management team continues to successfully execute our business plan and we look forward to routinely communicating our progress to our shareholders " . About Urigen N . A . , Inc . Urigen N . A . is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders . Urigen 's two lead programs target significant unmet medical needs and major market opportunities in urology . Urigen 's URG101 project targets chronic pelvic pain of bladder origin , which affects approximately 10 . 5 million men and women in North America . Urigen 's URG301 project targets acute urgency in patients diagnosed with an overactive bladder , another major unmet need that is insufficiently managed by presently available overactive bladder drugs . URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency . For further information , please visit Urigen 's website at http://www.urigen.com . Forward - Looking Statement This press release may contain forward - looking statements . These statements may be identified by the use of forward - looking terminology such as " anticipate , " " believe " , " continue " , " could " , " estimate " , " expect " , " intend " , " may " , " might , " " plan " , " potential " , " predict " , " should " , or " will " , or the negative thereof or other variations thereon or comparable terminology . Urigen has based these forward - looking statements on current expectations , assumptions , estimates and projections . While Urigen believes that these expectations , assumptions , estimates and projections are reasonable , such forward - looking statements are only predictions and involve known and unknown risks and uncertainties , many of which are beyond its control . Given these risks and uncertainties , investors and securityholders are cautioned not to place undue reliance on such forward - looking statements . Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments . Contact : Urigen N . A . , Inc . Martin E . Shmagin , 650 - 259 - 0239 Chief Financial Officer www.urigen.com or The Investor Relations Group Investor Relations : Adam Holdsworth / Rachel Colgate 212 - 825 - 3210